{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-017075","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.353259+00:00","generated_at":"2026-05-27T00:07:51.886538+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce","bullets":["Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.","Expects $1.1M severance charges; cash runway extended to second half of 2026.","Open-label extension for SIGNAL-AA Part A initiates in 1H'25; Part B dosing starts 1H'25 with topline data expected 1H'26.","Evaluating strategic options for tissue-targeted complement inhibitor platform, including ADX-097 and early-stage assets."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-017075","json":"https://secwatch.observer/filing/0000950170-25-017075.json","markdown":"https://secwatch.observer/filing/0000950170-25-017075.md","text":"https://secwatch.observer/filing/0000950170-25-017075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/0000950170-25-017075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-20250210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:07:51.886538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}